那屈肝素钙联合利伐沙班治疗肺动脉栓塞患者的临床效果  

Clinical Effect of Nadroparin Calcium Combined with Rivaroxaban in the Treatment of Patients with Pulmonary Embolism

作　　者：玉鸾 YU Luan(Liupanshui People's Hospital,Liupanshui 553000,China)

机构地区：[1]六盘水市人民医院,贵州六盘水553000

出　　处：《中外医学研究》2025年第2期43-46,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究那屈肝素钙联合利伐沙班治疗肺动脉栓塞(PE)患者的临床效果。方法:选取2022年3月—2024年3月六盘水市人民医院收治的90例PE患者。根据随机数表法将其分为对照组和观察组,各45例。两组均给予那屈肝素钙治疗,对照组给予华法林钠片,观察组给予利伐沙班片。比较两组治疗后临床疗效,治疗前后凝血功能、血气指标、心率、肺动脉收缩压(SPAP)及不良反应。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)均长于对照组,差异有统计学意义(P<0.05)。治疗后,观察组动脉血氧分压(PaO_(2))高于对照组,动脉血二氧化碳分压(PaCO_(2))、心率(HR)均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组SPAP均较治疗前降低,观察组SPAP低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:那屈肝素钙联合利伐沙班治疗PE患者效果显著,可改善凝血功能,调节血气指标、心率,降低SPAP,且不良反应少。Objective:To explore the clinical effect of Nadroparin Calcium combined with Rivaroxaban in the treatment of patients with pulmonary embolism(PE).Method:A total of 90 PE patients admitted to Liupanshui People's Hospital from March 2022 to March 2024 were selected.They were divided into control group and observation group according to random number table method,45 cases in each group.Both groups were given Nadroparin Calcium therapy,the control group was given Warfarin Sodium Tablets,and the observation group was given Rivaroxaban Tablets.The clinical efficacy after treatment,coagulation function,blood gas index,heart rate,pulmonary artery systolic pressure(SPAP)before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the prothrombin time(PT)and activated partial thromboplastin time(APTT)in the observation group were longer than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the arterial blood partial pressure of oxygen(PaO_(2))in the observation group was higher than that in the control group,and the arterial partial blood pressure of carbon dioxide(PaCO_(2))and heart rate(HR)in the observation group were lower than that in the control group,and the differences were statistically significant(P<0.05).After treatment,SPAP in both groups decreased than before treatment,SPAP in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Nadroparin Calcium combined with Rivaroxaban has significant effects in the treatment of PE patients,which can improve coagulation function,regulate blood gas index,heart rate,reduce SPAP,and have fewer adverse reactions.

关 键 词：肺动脉栓塞 那屈肝素钙 利伐沙班 凝血功能 血气指标 心率 

分 类 号：R563.5[医药卫生—呼吸系统]